Versant Venture Management, LLC Long-Term Concentrated

CIK: 0001560009 · Show all filings

Period: Q1 2017 (← Previous) (Next →)

Filing Date: Apr 7, 2017

Total Value ($000): $137,509,477 (100.0% shares, 0.0% debt)

Holdings (8)

— Achaogen, Inc. 23.5%

Value ($000) $32,323,465 Shares 1,281,152 Est. Cost $13050.00 Unrealized —

— Audentes Therapeutics, Inc. 22.4%

Value ($000) $30,788,417 Shares 1,806,832 Est. Cost $17810.00 Unrealized —

— Clovis Oncology, Inc. 18.9%

Value ($000) $25,940,177 Shares 407,416 Est. Cost $56000.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 15.0%

Value ($000) $20,558,764 Shares 2,215,384 Est. Cost $20.09 Unrealized -58.6%

— ImmuneDesign Corp. 10.9%

Value ($000) $15,015,828 Shares 2,208,210 Est. Cost $7580.00 Unrealized —

— Second Sight Medical Products, Inc. 4.0%

Value ($000) $5,436,500 Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— CymaBay Therapeutics, Inc. 3.3%

Value ($000) $4,508,983 Shares 1,048,601 Est. Cost $9830.00 Unrealized —

— OpGen, Inc. 2.1%

Value ($000) $2,937,343 Shares 2,554,211 Est. Cost $1150.00 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	Achaogen, Inc.	1,281,152	$32,323,465	23.5%	$13050.00	—	Common Stock	004449104
—	Audentes Therapeutics, Inc.	1,806,832	$30,788,417	22.4%	$17810.00	—	Common Stock	05070R104
—	Clovis Oncology, Inc.	407,416	$25,940,177	18.9%	$56000.00	—	Common Stock	189464100
OCUL	Ocular Therapeutix, Inc.	2,215,384	$20,558,764	15.0%	$20.09	-58.6%	Common Stock	67576A100
—	ImmuneDesign Corp.	2,208,210	$15,015,828	10.9%	$7580.00	—	Common Stock	45252L103
—	Second Sight Medical Products, Inc.	4,492,975	$5,436,500	4.0%	$1210.00	—	Common Stock	81362J100
—	CymaBay Therapeutics, Inc.	1,048,601	$4,508,983	3.3%	$9830.00	—	Common Stock	23257D103
—	OpGen, Inc.	2,554,211	$2,937,343	2.1%	$1150.00	—	Common Stock	68373L109